Phase 2 Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naive and Relapsed/Refractory Chronic Lymphocytic Leukemia

CONCLUSIONSOBIN, IBR, and VEN in combination have a tolerable safety profile in both RR and TN CLL patients with the majority of toxicities being hematologic. This regimen has a high mid-therapy response rate (92%) in RR patients with early MRD negative responses. EOT responses in TN and RR patients will be presented at the meeting.DisclosuresMaddocks: Teva: Honoraria; AstraZeneca: Honoraria; Pharmacyclics/Janssen: Honoraria; Novartis: Research Funding; Pharmacyclics: Research Funding; Merck: Research Funding; BMS: Research Funding. Jones: Celgene: Employment, Equity Ownership.

Source: Blood - November 21, 2018 Category: Hematology Authors: Rogers, K. A., Huang, Y., Ruppert, A. S., Awan, F. T., Hoffman, C., Maddocks, K. J., Reid, M., Woyach, J. A., Whitlow, T., Jones, J. A., Byrd, J. C. Tags: 642. CLL: Therapy, excluding Transplantation: Advances in Frontline Therapy of CLL Source Type: research